Department of Oncology-Pathology
The Department of Oncology-Pathology conducts basic, translational and clinical research and educational activities related to cancer.
New publication in Human Reproduction
New publication in Human Reproduction
A multicenter study including all women with breast cancer undergoing treatment for fertility preservation in Sweden revealed efficacy and safety of the procedures.
New top publication in Science Advances
New top publication in Science Advances
A novel autophagy inhibitor from Sprint Bioscience developed in collaboration with OnkPat improves the efficacy of immunotherapy in preclinical tumor models.
New funding opportunities 2020 from Cancer Research KI
The fundings include: Blue Sky Grant for Innovative Cancer Research & Technology, Translational Seed Funding as well as KI and Mayo Clinic Collaborative Call in Breast Cancer.
Two OnkPat employments financed via the Swedish Cancer Society
Two OnkPat employments financed via the Swedish Cancer Society
Senior Clinical Investigator Award goes to Kenny Rodriguez-Wallberg and Junior Clinical Investigator Award goes to Hildur Helgadottir, both at OnkPat.
Grander Ambitions for Discovering New Cancer Therapies – carrying on the legacy of Professor Dan Grandér
Dan Grandér (1964-2017), MD, PhD, Professor, and colleagues have published a groundbreaking article in Science Advances entitled, “Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death”. Dan Grandér was head of the Department of Oncology-Pathology before his passing away in October 2017.
New potential treatment of breast cancer
New potential treatment of breast cancer
The study investigated the addition of pembrolizumab, an anti-PD-1 antibody, to standard preoperative chemotherapy in triple negative breast cancer. Pembrolizumab+chemotherapy led to pathological complete response (pCR, no invasive cancer in the breast or lymph nodes at surgery) in 64,8% of patients, compared with 51,2% in patients treated with placebo+chemotherapy. The combination of pembrolizumab+ chemotherapy was well-tolerated. Extended follow-up is expected to show whether the observed improvement in pCR will translate into better survival. Theodoros Foukakis is the national coordinator of the study in Sweden and Prof Jonas Bergh is a member of the international steering committee for the trial.
Joseph Carlson receives financing from STINT
STINT is investing 4.4 million SEK in eight different research projects within the program Joint Brazilian-Swedish Research Collaboration for the period 2020–2023. Joseph Carlson at Department of Oncology-Pathology is one of the researchers receiving funding for his project "Fighting Global Cancer: A Swedish-Brazilian partnership focused on research, education and innovation".
Cheap drug may alleviate treatment-resistance in leukemia
Cheap drug may alleviate treatment-resistance in leukemia
In a study published in the journal EMBO Molecular Medicine Sean Rudd at OnkPat with colleagues show that a common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia, one of the most common forms of blood cancer. The researchers will now launch a clinical study to test the new combination treatment in patients.